Curaleaf Holdings (CURA) Fair Value & Analysis
Healthcare · CA · Market cap C$4.3B
Fair value as of: Jun 24, 2026
From 14 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from C$5.39 to C$9.72 (+80.3%) since Jun 23, 2026. Share price +5.2% over the past month.
Price vs Fair Value (12 months)
12‑month range C$2.84 – C$16.77 · fair‑value band C$7.29 – C$12.16 · the C$13.19 price screens above the C$9.72 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Curaleaf Holdings (CURA) currently trades at C$13.19, while our model-based Fair Value estimate is C$9.72 — implying the stock looks roughly 26.3% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Curaleaf Holdings generated revenue of C$1.3B at a net margin of -7.8%. Revenue grew 5.7% year over year. It earns a return on equity of -8.7%. Net debt stands at C$934M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Curaleaf Holdings reported revenue of C$1.3B in FY2025 versus C$1.2B in FY2021, a compound +1.6%/yr. Reported net income was −C$235M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Curaleaf Holdings (CURA) undervalued?
What is the fair value of CURA?
What is the quality score of CURA?
What is the revenue of Curaleaf Holdings (CURA)?
What is the net profit margin of CURA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.